Abstract:Farnesoid X receptor (FXR) agonists can reverse dysregulated bile acid metabolism, and thus, they are potential therapeutics to prevent and treat nonalcoholic fatty liver disease. The low success rate of FXR agonists' R&D and the side effects of clinical candidates such as obeticholic acid make it urgent to discover new chemotypes. Unfortunately, structure-based virtual screening (SBVS) that can speed up drug discovery has rarely been reported with success for FXR, which was likely hindered by the failure in addressing protein flexibility. To address this issue, we devised human FXR (hFXR)-specific ensemble learning models based on pose filters from 24 agonist-bound hFXR crystal structures and coupled them to traditional SBVS approaches of the FRED docking plus Chemgauss4 scoring function. It turned out that the hFXR-specific pose filter ensemble (PFE) was able to improve ligand enrichment significantly, which rendered 3RUT-based SBVS with its PFE the ideal approach for FXR agonist discovery. By screening of the Specs chemical library and in vitro FXR transactivation bioassay, we identified a new class of FXR agonists with compound XJ034 as the representative, which would have been missed if the PFE was not coupled. Following that, we performed in-depth biological studies which demonstrated that XJ034 resulted in a downtrend of intracellular triglyceride in vitro, significantly decreased the serum/liver TG in high fat diet-induced C57BL/6J obese mice, and more importantly, showed metabolic stabilities in both plasma and liver microsomes. To provide insight into further structure-based lead optimization, we solved the crystal structure of hFXR complexed with compound XJ034, uncovering a unique hydrogen bond between compound XJ034 and residue Y375. The current work highlights the power of our pose filter-based ensemble learning approach in terms of scaffold hopping and provides a promising lead compound for further development.

Structural insights into the heterodimeric complex of the nuclear receptors FXR and RXR

Ligand Binding and Heterodimerization with Retinoid X Receptor Α (rxrα) Induce Farnesoid X Receptor (FXR) Conformational Changes Affecting Coactivator Binding

Structural Basis of the Farnesoid X Receptor/retinoid X Receptor Heterodimer on Inverted Repeat DNA

Structural Basis for Retinoic X Receptor Repression on the Tetramer

Pose Filter-Based Ensemble Learning Enables Discovery of Orally Active, Nonsteroidal Farnesoid X Receptor Agonists

Machine learning- and structure-based discovery of a novel chemotype as FXR agonists for potential treatment of nonalcoholic fatty liver disease

Design, synthesis and biological evaluations of novel farnesoid X receptor (FXR) agonists

Asymmetric binding of coactivator SRC1 to FXR-RXR and allosteric communication within the complex

Simulations reveal unique roles for the FXR hinge in the FXR-RXR nuclear receptor heterodimer

FXR: structures, biology, and drug development for NASH and fibrosis diseases

The farnesoid X receptor activates transcription independently of RXR at non-canonical response elements

A Novel Class of Natural FXR Modulators with a Unique Mode of Selective Co‐regulator Assembly

Retinoid X Receptor Heterodimers in Hepatic Function: Structural Insights and Therapeutic Potential

[Progress in the Ligands and Their Complex Structures of Farnesoid X Receptor].

STRUCTURAL BASIS FOR BILE ACID BINDING AND ACTIVATION OF THE NUCLEAR RECEPTOR FXR

Mutation of Two Residues Converts the Ligand-Binding Domain of RXRα into a Uniform Monomer Without Impairing the Binding of Retinoic Acid and Cofactors.

Mutations That Alter Ligand-induced Switches and Dimerization Activities in the Retinoid X Receptor

Computational Insight into the Allosteric Activation Mechanism of Farnesoid X Receptor

Design, Synthesis, and Biological Evaluation of Novel Nonsteroidal Farnesoid X Receptor (FXR) Antagonists: Molecular Basis of FXR Antagonism.

3D-QSAR and Molecular Dynamics Study of Isoxazole Derivatives to Identify the Structural Requirements for Farnesoid X Receptor (FXR) Agonists

Farnesoid X Receptor (FXR): Structures and Ligands.